Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - Shire plc | dp22738_8k.htm |
|
Exhibit 99.01
|
|
|
Press Release
|
 |
|
www.shire.com
|
|
BLOCK LISTING SIX MONTHLY RETURN
May 24, 2011 - Shire plc (LSE: SHP, NASDAQ: SHPGY)
|
Name of applicant:
|
Shire plc
|
|||
|
Name of scheme:
|
1996 Executive Share Option Scheme
|
|||
|
Period of return:
|
From:
|
November 23, 2010
|
To:
|
May 22, 2011
|
|
Balance of unallotted securities under scheme(s) from previous return:
|
78,597
|
|||
|
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):
|
Nil
|
|||
|
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):
|
Nil
|
|||
|
Equals: Balance under scheme(s) not yet issued/allotted at end of period:
|
78,597
|
|||
|
Name of applicant:
|
Shire plc
|
|||
|
Name of scheme:
|
2000 Executive Share Option Scheme
|
|||
|
Period of return:
|
From:
|
November 23, 2010
|
To:
|
May 22, 2011
|
|
Balance of unallotted securities under scheme(s) from previous return:
|
3,814,877
|
|||
|
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):
|
Nil
|
|||
|
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):
|
105,196
|
|||
|
Equals: Balance under scheme(s) not yet issued/allotted at end of period:
|
3,709,681
|
|||
|
Name of applicant:
|
Shire plc
|
|||
|
Name of scheme:
|
Shire Sharesave Scheme
|
|||
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX
|
Period of return:
|
From:
|
November 23, 2010
|
To:
|
May 22, 2011
|
|
Balance of unallotted securities under scheme(s) from previous return:
|
5,392
|
|||
|
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):
|
Nil
|
|||
|
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):
|
Nil
|
|||
|
Equals: Balance under scheme(s) not yet issued/allotted at end of period:
|
5,392
|
|||
|
Name of applicant:
|
Shire plc
|
|||
|
Name of scheme:
|
Biochem Pharma Stock Option Plan
|
|||
|
Period of return:
|
From:
|
November 23, 2010
|
To:
|
May 22, 2011
|
|
Balance of unallotted securities under scheme(s) from previous return:
|
3,873
|
|||
|
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):
|
Nil
|
|||
|
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):
|
Nil
|
|||
|
Equals: Balance under scheme(s) not yet issued/allotted at end of period:
|
3,873
|
|||
|
Name of contact:
|
Tony Guthrie, Deputy Company Secretary
|
|
Address of contact:
|
Hampshire International Business Park
Basingstoke, Hampshire, RG24 8EP
|
|
Telephone number of contact:
|
01256 894746
|
For further information please contact:
|
Investor Relations
|
Eric Rojas (erojas@shire.com)
|
+1 781 482 0999
|
|
Sarah Elton-Farr (seltonfarr@shire.com)
|
+44 1256 894157
|
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX
Notes to editors
SHIRE PLC
Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company’s website: www.shire.com.
"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995
Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, the Company’s results could be materially adversely affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of research, development, approval, reimbursement, manufacturing and commercialization of the Company’s Specialty Pharmaceutical and Human Genetic Therapies products, as well as the ability to secure and integrate new products for commercialization and/or development; government regulation of the Company’s products; the Company’s ability to manufacture its products in sufficient quantities to meet demand; the impact of competitive therapies on the Company’s products; the Company’s ability to register, maintain and enforce patents and other intellectual property rights relating to its products; the Company’s ability to obtain and maintain government and other third-party reimbursement for its products; and other risks and uncertainties detailed from time to time in the Company’s filings with the Securities and Exchange Commission.
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX